CA3183735A1 - Compositions and methods for inducing an immune response against coronavirus - Google Patents

Compositions and methods for inducing an immune response against coronavirus

Info

Publication number
CA3183735A1
CA3183735A1 CA3183735A CA3183735A CA3183735A1 CA 3183735 A1 CA3183735 A1 CA 3183735A1 CA 3183735 A CA3183735 A CA 3183735A CA 3183735 A CA3183735 A CA 3183735A CA 3183735 A1 CA3183735 A1 CA 3183735A1
Authority
CA
Canada
Prior art keywords
coronavirus
cpg
peptide
antigen
spike protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3183735A
Other languages
English (en)
French (fr)
Inventor
Martin P. STEINBUCK
Lochana M. SEENAPPA
Peter C. Demuth
Christopher M. HAQQ
Lisa MCNEIL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elicio Therapeutics Inc
Original Assignee
Elicio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elicio Therapeutics Inc filed Critical Elicio Therapeutics Inc
Publication of CA3183735A1 publication Critical patent/CA3183735A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3183735A 2020-06-26 2021-06-25 Compositions and methods for inducing an immune response against coronavirus Pending CA3183735A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063044773P 2020-06-26 2020-06-26
US63/044,773 2020-06-26
US202063064836P 2020-08-12 2020-08-12
US63/064,836 2020-08-12
US202063124200P 2020-12-11 2020-12-11
US63/124,200 2020-12-11
US202163145200P 2021-02-03 2021-02-03
US63/145,200 2021-02-03
PCT/US2021/039134 WO2021263131A1 (en) 2020-06-26 2021-06-25 Compositions and methods for inducing an immune response against coronavirus

Publications (1)

Publication Number Publication Date
CA3183735A1 true CA3183735A1 (en) 2021-12-30

Family

ID=79281915

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3183735A Pending CA3183735A1 (en) 2020-06-26 2021-06-25 Compositions and methods for inducing an immune response against coronavirus

Country Status (9)

Country Link
US (1) US20230263882A1 (https=)
EP (1) EP4171574A4 (https=)
JP (1) JP2023532290A (https=)
KR (1) KR20230044404A (https=)
AU (1) AU2021294342A1 (https=)
BR (1) BR112022026580A2 (https=)
CA (1) CA3183735A1 (https=)
MX (1) MX2023000041A (https=)
WO (1) WO2021263131A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI884296B (zh) * 2020-08-11 2025-05-21 美商碩騰服務公司 抗冠狀病毒疫苗
CA3170743A1 (en) * 2020-08-31 2022-03-03 Susanne RAUCH Multivalent nucleic acid based coronavirus vaccines
WO2023114570A1 (en) * 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions and methods for long-lasting germinal center responses to a priming immunization
WO2023159081A2 (en) * 2022-02-15 2023-08-24 Ohio State Innovation Foundation Nanotechnology based intranasal vaccine for covid-19
CN114752631B (zh) * 2022-06-15 2022-09-02 中国人民解放军军事科学院军事医学研究院 Rna及包含其的新型冠状病毒疫苗和制备方法
WO2024226775A2 (en) * 2023-04-26 2024-10-31 Elicio Therapeutics, Inc. Compositions containing polynucleotide and polypeptide amphiphiles and methods of use thereof
WO2025240477A1 (en) * 2024-05-17 2025-11-20 The Regents Of The University Of California Methods and materials for enhancing delivery of nucleic acid to cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1629104A4 (en) * 2003-06-04 2006-11-02 Bioleaders Corp CELL SURFACE EXPRESSION VECTOR OF SARS VIRUS ANTIGEN AND TRANSFORMED MICROORGANISMS
WO2006009011A1 (ja) * 2004-07-15 2006-01-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute コロナウイルススパイクｓ１融合蛋白及びその発現ベクター
JP6375289B2 (ja) * 2012-04-05 2018-08-15 マサチューセッツ インスティテュート オブ テクノロジー 免疫刺激組成物およびその使用方法
JP6487850B2 (ja) * 2013-11-29 2019-03-20 テルモ株式会社 アジュバント組成物およびこれを含むワクチン組成物、並びにこれらの製造方法
DK3758712T3 (da) * 2018-03-02 2025-08-04 Elicio Therapeutics Inc Cpg-amfifiler og anvendelser deraf
JP7438604B2 (ja) * 2020-02-07 2024-02-27 モデルナティエックス インコーポレイテッド ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン

Also Published As

Publication number Publication date
EP4171574A1 (en) 2023-05-03
JP2023532290A (ja) 2023-07-27
AU2021294342A1 (en) 2023-02-23
MX2023000041A (es) 2023-03-10
EP4171574A4 (en) 2024-10-23
BR112022026580A2 (pt) 2023-01-24
US20230263882A1 (en) 2023-08-24
KR20230044404A (ko) 2023-04-04
WO2021263131A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
US20230263882A1 (en) Compositions and methods for inducing an immune response against coronavirus
US20230277652A1 (en) Nucleic acid vaccines for coronavirus
CN110381994B (zh) 用于诱导针对寨卡病毒的免疫应答的核苷修饰的rna
US20210317169A1 (en) Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using same
US8557247B2 (en) Lyophilised antigen composition
Chen et al. A simple but effective cancer vaccine consisting of an antigen and a cationic lipid
JP6211383B2 (ja) カチオン脂質による免疫応答の刺激
CN116670267A (zh) 流感病毒的四价mRNA疫苗
JP2017513956A (ja) 核酸ワクチン
EP1037662A1 (en) Method to enhance an immune response of nucleic acid vaccination
JP2014518620A (ja) リポソーム製剤
CN117580587B (zh) 基于源自SARS-CoV-2奥密克戎毒株的序列的冠状病毒核酸疫苗
CN116583296A (zh) 使用核苷修饰mrna的通用流感疫苗
TW202502375A (zh) 用於治療披衣菌之組合物
CN117083291B (zh) 基于源自SARS-CoV-2 Delta毒株的序列的冠状病毒核酸疫苗
Zeng et al. Novel adjuvant delivery system constructed by alum-emulsion hybrid nanoparticles with TLR9 agonists boosts vaccine immunity
CN117460827A (zh) 狂犬病核酸疫苗
TW202500750A (zh) 用於治療痤瘡的組成物
KR20250099770A (ko) 코로나바이러스에 대한 백신
CN116507344A (zh) 用于诱导针对冠状病毒的免疫应答的组合物和方法
HK40097857A (zh) 用於诱导针对冠状病毒的免疫应答的组合物和方法
CN118695850A (zh) 通用流感疫苗及使用方法
KR20240158819A (ko) 섬유아세포 활성화 단백질의 면역우세 에피토프 펩타이드 및 이의 용도
AU2013213688A1 (en) Lyophilised antigen composition

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251224

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260206

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260224